Related Experiment Video
Updated: Jun 19, 2026

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
Novel loci interacting epistatically with bone morphogenetic protein receptor 2 cause familial pulmonary arterial
Laura Rodriguez-Murillo1, Ryan Subaran, William C L Stewart
1Division of Statistical Genetics, Department of Biostatistics, Columbia University Medical Center, New York, New York, USA.
Background:
Familial pulmonary arterial hypertension (FPAH) is a rare, autosomal-dominant, inherited disease with low penetrance. Mutations in the bone morphogenetic protein receptor 2 (BMPR2) have been identified in at least 70% of FPAH patients. However, the lifetime penetrance of these BMPR2 mutations is 10% to 20%, suggesting that genetic and/or environmental modifiers are required for disease expression. Our goal in this study was to identify genetic loci that may influence FPAH expression in BMPR2 mutation carriers.
Methods:
We performed a genome-wide linkage scan in 15 FPAH families segregating for BMPR2 mutations. We used a dense single-nucleotide polymorphism (SNP) array and a novel multi-scan linkage procedure that provides increased power and precision for the localization of linked loci.
Results:
We observed linkage evidence in four regions: 3q22 ([median log of the odds (LOD) = 3.43]), 3p12 (median LOD) = 2.35), 2p22 (median LOD = 2.21), and 13q21 (median LOD = 2.09). When used in conjunction with the non-parametric bootstrap, our approach yields high-resolution to identify candidate gene regions containing putative BMPR2-interacting genes. Imputation of the disease model by LOD-score maximization indicates that the 3q22 locus alone predicts most FPAH cases in BMPR2 mutation carriers, providing strong evidence that BMPR2 and the 3q22 locus interact epistatically.
Conclusions:
Our findings suggest that genotypes at loci in the newly identified regions, especially at 3q22, could improve FPAH risk prediction in FPAH families. We also suggest other targets for therapeutic intervention.
Insights
Genetic modifiers influence familial pulmonary arterial hypertension (FPAH) in BMPR2 mutation carriers. A genome-wide scan identified new loci, particularly 3q22, that may improve FPAH risk prediction.
Area of Science:
- Genetics
- Pulmonary Hypertension
- Molecular Biology
Background:
- Familial pulmonary arterial hypertension (FPAH) is a rare, autosomal-dominant disease with incomplete penetrance.
- Bone morphogenetic protein receptor 2 (BMPR2) mutations are found in 70% of FPAH patients, but only 10-20% develop the disease.
- Genetic and environmental factors likely modify BMPR2 mutation penetrance.
Purpose of the Study:
- To identify genetic loci influencing FPAH expression in BMPR2 mutation carriers.
- To understand the genetic basis of variable disease penetrance in FPAH.
Main Methods:
- Genome-wide linkage scan in 15 FPAH families with BMPR2 mutations.
- Utilized dense single-nucleotide polymorphism (SNP) arrays and a novel multi-scan linkage procedure.
- Employed non-parametric bootstrap and LOD-score maximization for high-resolution locus identification.
Main Results:
- Identified linkage evidence in four chromosomal regions: 3q22, 3p12, 2p22, and 13q21.
- The 3q22 locus showed the strongest linkage (median LOD = 3.43) and appears to interact epistatically with BMPR2.
- The identified regions contain candidate genes potentially interacting with BMPR2.
Conclusions:
- Genotypes at newly identified loci, especially 3q22, may enhance FPAH risk prediction in BMPR2 mutation carriers.
- These findings suggest potential new therapeutic targets for FPAH.
- Further research into these loci can elucidate FPAH pathogenesis.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Pleiotropy
Epistasis
Pharmacogenomics: Identification of New Drug Targets
